Developing novel theory and methods for understanding the genetic architecture of complex human traits (R21 Clinical Trial Not Allowed)
ID: 350333Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $275K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/350333

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-301.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity aimed at developing innovative theories and methods to understand the genetic architecture of complex human traits through the R21 grant mechanism, which excludes clinical trials. This initiative encourages interdisciplinary research that integrates genetic, environmental, and behavioral data to explore health-related traits, with a particular focus on population-scale genetic cohorts and advanced computational techniques. The total funding available is up to $275,000 over two years, with applications due starting January 16, 2024, and continuing through 2027. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-301-Full-Announcement.html
    PAR-23-301.html
    The Department of Health and Human Services is issuing a funding opportunity through the National Institutes of Health (NIH) aimed at developing innovative theories and methods to better understand the genetic architecture of complex human traits. This NOFO (PAR-23-301) specifically invites applications for exploratory and developmental research (R21 grants), excluding clinical trials. It focuses on interdisciplinary approaches that weave together genetic, environmental, and behavioral data to unravel the complexities of human traits related to health and disease. Key aspects of the proposal include the emphasis on population-scale genetic cohorts and advanced computational techniques to analyze traits across diverse populations. Eligible applicants are encouraged to adopt systems epidemiology modeling, particularly regarding cancer risk factors. Funding includes a combined budget of up to $275,000 over two years, with a limit of $200,000 per year. Applications must conform to specific guidelines and are evaluated based on innovation, significance, and overall approach. The submission timeline starts on January 16, 2024, with deadlines for various application types leading up to 2027. The initiative represents a significant federal investment to advance genetics research, thereby enhancing understanding of disease susceptibility and promoting equitable health outcomes.
    Similar Opportunities
    Developing novel theory and methods for understanding the genetic architecture of complex human traits (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Developing novel theory and methods for understanding the genetic architecture of complex human traits" under the R01 Clinical Trial Not Allowed grant program. This initiative aims to support interdisciplinary research that enhances the understanding of how genetic and non-genetic factors contribute to complex trait variation among individuals and populations, encouraging innovative theoretical approaches and the use of large-scale datasets. The program is significant for advancing genetic research, addressing health disparities, and promoting collaborative research environments. Interested applicants, including higher education institutions and non-profits, must submit their applications by February 5, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. More details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-23-302.html.
    Advancing Genomic Medicine Research (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advancing Genomic Medicine Research (R21 Clinical Trial Optional)" aimed at stimulating innovative research in the integration of genomic information into clinical care, particularly for populations experiencing health disparities. This initiative encourages proposals that address implementation science, barriers to genomic medicine, and the integration of genomic data with health and social determinants, with a focus on enhancing health equity among underrepresented groups. The grant provides funding up to $250,000, with applications open from November 1, 2023, until the close date of February 11, 2025. Interested applicants can find more information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Advancing Genomic Medicine Research (R03 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advancing Genomic Medicine Research (R03 Clinical Trial Not Allowed)" aimed at stimulating innovation in the implementation and sharing of genomic information in clinical care across diverse populations. This initiative encourages applications for small research projects that explore the integration of genomic data into clinical practice, assess barriers to implementation, and develop innovative data analysis techniques, particularly focusing on underrepresented populations in genomic research. The maximum budget for each application is $50,000 over a two-year period, with a total funding expectation of approximately $150,000 for FY 2024. Interested applicants must submit their proposals by February 12, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required) to support innovative research projects at the preliminary or conceptual stage, particularly those with the potential to advance biomedical, behavioral, or clinical research. Applicants must include at least one clinical trial in their proposals, focusing on mechanistic studies that align with the scientific missions of participating NIH Institutes and Centers. This funding opportunity is crucial for stimulating novel research that challenges conventional methods and improves clinical practices, with a maximum budget of $275,000 available for a two-year project, and no more than $200,000 allocated in any single year. Interested applicants should adhere to strict submission guidelines and can contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV for assistance; the application deadline is January 7, 2025.
    Investigator Initiated Research in Computational Genomics and Data Science (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Investigator Initiated Research in Computational Genomics and Data Science (R21 Clinical Trial Not Allowed)" aimed at supporting innovative research in computational genomics, data science, and bioinformatics. This grant seeks to enhance analytical methodologies, develop and refine software tools, and integrate various genomic data types to improve human health outcomes, with a focus on applications that are broadly applicable across diseases and biological systems. Eligible applicants include a diverse range of organizations, particularly those from underrepresented groups in genomic science, and must adhere to strict application guidelines, including the submission of a Data Management and Sharing Plan. The application deadline is January 7, 2025, and interested parties can find more information and submit their applications electronically through Grants.gov or contact the NIH OER Webmaster at grantsinfo@nih.gov for assistance.
    Investigator-Initiated Research in Genomics and Health Equity (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Investigator-Initiated Research in Genomics and Health Equity (R21 Clinical Trial Optional)" aimed at supporting small-scale research projects that enhance health equity through genomic research. The initiative seeks to develop innovative approaches and metrics to ensure the equitable application of genomics in improving health outcomes for U.S. populations, particularly focusing on historically underrepresented groups in biomedical research. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofit organizations, and state governments, with funding available up to $200,000 annually for a maximum of two years. Interested parties should submit their applications by July 8, 2025, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage for more details at https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-23-018.html.
    NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Research Grant Program (Parent R21), aimed at supporting innovative early-stage research projects in the biomedical, behavioral, and clinical fields. This funding opportunity is specifically designed for basic experimental studies involving human participants, with a focus on developing novel techniques or methodologies that can significantly advance scientific understanding. Eligible applicants, including small businesses and various institutions, can receive funding of up to $275,000 over a two-year period, with applications accepted on a rolling basis until the close date of January 7, 2025. For further details, interested parties can contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PA-20-196.html.
    NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed) to support innovative biomedical and clinical research projects. This grant aims to foster exploratory research that may involve significant risks but has the potential for breakthroughs or the development of novel methodologies in health-related fields. The program is crucial for advancing research that addresses pressing health challenges and encourages applications that present new scientific ideas distinct from traditional R01 projects. Eligible applicants include a wide range of institutions, including higher education institutions, nonprofits, and for-profit organizations, both domestic and foreign, with a budget limit of $275,000 over two years and a maximum request of $200,000 in any single year. Interested parties should submit their applications electronically by January 7, 2025, and can contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV for further assistance.
    Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed) grant. This funding opportunity aims to support projects that address critical needs for clinical trial readiness in rare diseases, specifically by facilitating the development of biomarkers and clinical outcome measures essential for trial design. The initiative is particularly important for advancing research on diseases affecting fewer than 200,000 individuals in the U.S., enhancing the likelihood of successful clinical trials. Applicants can request up to $275,000 over two years, with a submission deadline of October 17, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-159.html.
    Functional Validation and/or Characterization of Genes or Variants Implicated in Substance Use Disorders (R21/R33 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Functional Validation and/or Characterization of Genes or Variants Implicated in Substance Use Disorders" (R21/R33), aimed at supporting research projects that explore the genetic underpinnings of substance use disorders. This initiative encourages researchers to utilize innovative methodologies, such as CRISPR technologies, to validate addiction-relevant genes and characterize their roles in living organisms or human organoid systems, thereby enhancing the understanding of neurobiological mechanisms associated with addiction. The funding allows for up to $125,000 per year for the R21 phase over two years and up to $250,000 annually for the R33 phase over three years, with applications due by 5:00 PM local time on February 3, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-24-267.html.